In this issue
This interview with a top thought leader from McGill University in Canada educates clinicians on important innovations in the field of blood-based neurology biomarkers. Read now to find out how the clinical application of a biomarker test for neurofilament light chain (NfL) can help fulfil unmet needs in the management of relapsing multiple sclerosis.
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.